The p38 mitogen-activated protein kinase signaling cascade in CD4 T cells

Arthritis Research and Therapy

Volumn 8, Issue 2, 2006, Pages

  Dodeller, Francis ^a   Schulze Koops, Hendrik ^a  

^a UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

4 (4 FLUOROPHENYL) 2 (4 METHYLSULFINYLPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; 4 [4 (4 FLUOROPHENYL) 1 (3 PHENYLPROPYL) 5 (4 PYRIDINYL) 1H IMIDAZOL 2 YL] 3 BUTYN 1 OL; ACTIVATING TRANSCRIPTION FACTOR 2; ACTIVATING TRANSCRIPTION FACTOR 4; ANTISENSE OLIGONUCLEOTIDE; CYTOKINE; DORAMAPIMOD; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 13; INTERLEUKIN 2; INTERLEUKIN 4; INTERLEUKIN 5; MITOGEN ACTIVATED PROTEIN KINASE P38; MITOGEN ACTIVATED PROTEIN KINASE P38 INHIBITOR; STAT PROTEIN; STAT4 PROTEIN; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG; VX 702;

ACUTE CORONARY SYNDROME; ALLERGIC DISEASE; ANTIINFLAMMATORY ACTIVITY; AUTOIMMUNE DISEASE; BRONCHITIS; CD4+ T LYMPHOCYTE; CELL TYPE; CLINICAL EFFECTIVENESS; CLINICAL TRIAL; CYTOKINE RELEASE; DRUG EFFICACY; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME INACTIVATION; ENZYME INHIBITION; ENZYME SUBSTRATE; GENETIC TRANSCRIPTION; HUMAN; IMMUNE DEFICIENCY; IMMUNOMODULATION; IN VITRO STUDY; IN VIVO STUDY; INFLAMMATORY DISEASE; LYMPHOCYTE FUNCTION; NEUROTOXICITY; NONHUMAN; PATHOGENESIS; PROTEIN ANALYSIS; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVIEW; RHEUMATOID ARTHRITIS; RNA STABILITY; SEPSIS; SIGNAL TRANSDUCTION; SYSTEMATIC REVIEW; SYSTEMIC VASCULITIS; ANIMAL; ENZYMOLOGY; METABOLISM;

ANIMALS; CD4-POSITIVE T-LYMPHOCYTES; HUMANS; P38 MITOGEN-ACTIVATED PROTEIN KINASES; SIGNAL TRANSDUCTION;

EID: 33645723895     PISSN: 14786354     EISSN: None     Source Type: Journal    
DOI: 10.1186/ar1905     Document Type: Review

References (130)

1. Han J, Lee JD, Bibbs L, Ulevitch RJ: A MAP kinase targeted by endotoxin and hyperosmolarity in mammalian cells. Science 1994, 265:808-811.
2. Lee JC, Laydon JT, McDonnell PC, Gallagher TF, Kumar S, Green D, McNulty D, Blumenthal MJ, Heys JR, Landvatter SW, et al.: A protein kinase involved in the regulation of inflammatory cytokine biosynthesis. Nature 1994, 372:739-746.
3. Ambrosino C, Nebreda AR: Cell cycle regulation by p38 MAP kinases. Biol Cell 2001, 93:47-51.
4. Harper SJ, LoGrasso P: Signalling for survival and death in neurones: the role of stress-activated kinases, JNK and p38. Cell Signal 2001, 13:299-310.
5. Rincon M, Flavell RA, Davis RA: The JNK and p38 MAP kinase signaling pathways in T cell-mediated immune responses. Free Radic Biol Med 2000, 28:1328-1337.
6. Mosmann TR, Cherwinski H, Bond MW, Giedlin MA, Coffman RL: Two types of murine helper T cell clone. I. Definition according to profiles of lymphokine activities and secreted proteins. J Immunol 1986, 136:2348-2357.
7. Skapenko A, Leipe J, Lipsky P, Schulze-Koops H: The role of the T cell in autoimmune inflammation. Arthritis Res Ther 2005, 7: S4-S14.
8. Schulze-Koops H, Lipsky PE, Kavanaugh AF, Davis LS: Elevated Th1- or Th0-like cytokine mRNA in peripheral circulation of patients with rheumatoid arthritis: modulation by treatment with anti-ICAM-1 correlates with clinical benefit. J Immunol 1995, 155:5029-5037.
9. Maizels RM, Yazdanbakhsh M: Immune regulation by helminth parasites: cellular and molecular mechanisms. Nat Rev Immunol 2004, 3:733-744.
10. Kay AB: Allergy and allergic diseases. First of two parts. N Engl J Med 2001, 344:30-37.
11. Rocken M, Racke M, Shevach EM: IL-4-induced immune deviation as antigen-specific therapy for inflammatory autoimune disease. Immunol Today 1996, 17:225-231.
12. Skapenko A, Wendler J, Lipsky PE, Kalden JR, Schulze-Koops H: Altered memory T cell differentiation in patients with early rheumatoid arthritis. J Immunol 1999, 163:491-499.
13. Murphy KM, Reiner SL: The lineage decisions of helper T cells. Nat Rev Immunol 2002, 2:933-944.
14. Hale KK, Trollinger D, Rihanek M, Manthey CL: Differential expression and activation of p38 mitogen-activated protein kinase α, β, γ, and δ in inflammatory cell lineages. J Immunol 1999, 162:4246-4252.
15. Chen G, Porter MD, Bristol JR, Fitzgibbon MJ, Pazhanisamy S: Kinetic mechanism of the p38-alpha MAP kinase: phosphoryl transfer to synthetic pepticles. Biochemistry 2000, 39:2079-2087.
16. LoGrasso PV, Frantz B, Rolando AM, O'Keefe SJ, Hermes JD, O'Neill EA: Kinetic mechanism for p38 MAP kinase. Biochemistry 1997, 36:10422-10427.
17. Frantz B, Klatt T, Pang M, Parsons J, Rolando A, Williams H, Tocci MJ, O'Keefe SJ, O'Neill EA: The activation state of p38 mitogen-activated protein kinase determines the efficiency of ATP competition for pyridinylimidazole inhibitor binding. Biochemistry 1998, 37:13846-13853.
18. Lee MR, Dominguez C: MAP kinase p38 inhibitors: clinical results and an intimate look at their interactions with p38alpha protein. Curr Med Chem 2005, 12:2979-2994.
19. Birrell MA, Wong S, McCluskie K, Catley MC, Hardarker EL, Haj-Yahia S, Belvisi MG: Second generation inhibitors demonstrate the involvement of p38 MAP kinase in post-transcriptional modulation of inflammatory mediator production in human and rodent airways. J Pharmacol Exp Ther 2005, DOI:jpet.105.093310.
20. Widmann C, Gibson S, Jarpe MB, Johnson GL: Mitogen-activated protein kinase: conservation of a three-kinase module from yeast to human. Physiol Rev 1999, 79:143-180.
21. Raingeaud J, Whitmarsh A, Barrett T, Derijard B, Davis R: MKK3-and MKK6-regulated gene expression is mediated by the p38 mitogen-activated protein kinase signal transduction pathway. Mol Cell Biol 1996, 16:1247-1255.
22. Derijard B, Raingeaud J, Barrett T, Wu IH, Han J, Ulevitch RJ, Davis RJ: Independent human MAP-kinase signal transduction pathways defined by MEK and MKK isoforms. Science 1995, 267:682-685.
23. Salojin KV, Zhang J, Delovitch TL: TCR and CD28 are coupled via ZAP-70 to the activation of the vav/rac-1-/Pak-1/p38 MAPK signaling pathway. J Immunol 1999, 163:844-853.
24. Zhang S, Han J, Sells MA, Chernoff J, Knaus UG, Ulevitch RJ, Bokoch GM: Rho family GTPases regulate p38 mitogen-activated protein kinase through the downstream mediator Pak-1. J Biol Chem 1995, 270:23934-23936.
25. Takekawa M, Saito H: A family of stress-inducible GADD45-like proteins mediate activation of the stress-responsive MTK1/MEKK4 MAPKKK. Cell 1998, 95:521-530.
26. Berenson LS, Ota N, Murphy KM: Issues in T-helper 1 development - resolved and unresolved. Immunol Rev 2004, 202:157-174.
27. Mita H, Tsutsui J, Takekawa M, Witten EA, Saito H: Regulation of MTK1/ MEKK4 kinase activity by its N-terminal autoinhibitory domain and GADD45 binding. Mol Cell Biol 2002, 22:4544-4555.
28. Lu B, Ferrandino AF, Flavell RA: Gadd45β is important for perpetuating cognate and inflammatory signals in T cells. Nat Immunol 2004, 5:38-44.
29. Takekawa M, Tatebayashi K, Itoh F, Adachi M, Imai K, Saito H: Smad-dependent GADD45beta expression mediates delayed activation of p38 MAP kinase by TGF-beta. EMBO J 2002, 21: 6473-6482.
30. Salvador JM, Mittelstadt PR, Guszczynski T, Copeland TD, Yamaguchi H, Appella E, Fornace AJ, Ashwell JD: Alternative p38 activation pathway mediated by T cell receptor-proximal tyrosine kinases. Nat Immunol 2005, 6:390-395.
31. Rudd CE: MAPK p38: alternative and nonstressful in T cells. Nat Immunol 2005, 6:368-370.
32. Farooq A, Zhou M-M: Structure and regulation of MAPK phos-phatases. Cell Signal 2004, 16:769-779.
33. Salvador JM, Mittelstadt PR, Belova GI, Fornace AJ, Ashwell JD: The autoimmune suppressor Gadd45α inhibits the T cell alternative p38 activation pathway. Nat Immunol 2005, 6:396-402.
34. Papa S, Zazzeroni F, Bubici C, Jayawardena S, Alvarez K, Matsuda S, Nguyen DU, Pham CG, Nelsbach AH, Melis T, et al.: Gadd45β mediates the NF-κB suppression of JNK signalling by targeting MKK7/JNKK2. Nat Cell Biol 2004, 6:146-153.
35. Pearson G, Robinson F, Beers Gibson T, Xu B-e, Karandikar M, Berman K, Cobb MH: Mitogen-activated protein (MAP) kinase pathways: regulation and physiological functions. Endocr Rev 2001, 22:153-183.
36. Barsyte-Lovejoy D, Galanis A, Sharrocks AD: Specificity determinants in MAPK signaling to transcription factors. J Biol Chem 2002, 277:9896-9903.
37. Sharrocks AD, Yang S-H, Galanis A: Docking domains and substrate-specificity determination for MAP kinases. Trends Biochem Sci 2000, 25:448-453.
38. Zhang Y, Liu G, Dong Z: MSK1 and JNKs mediate phosphorylation of STAT3 in UVA-irradiated mouse epidermal JB6 cells. J Biol Chem 2001, 276:42534-42542.
39. Zhang Y, Cho Y-Y, Petersen BL, Zhu F, Dong Z: Evidence of STAT1 phosphorylation modulated by MAPKs, MEK1 and MSK1. Carcinogenesis 2004, 25:1165-1175.
40. Wiggin GR, Soloaga A, Foster JM, Murray-Tait V, Cohen P, Arthur JSC: MSK1 and MSK2 are required for the mitogen- and stress-induced phosphorylation of CREB and ATF1 in fibroblasts. Mol Cell Biol 2002, 22:2871-2881.
41. Vermeulen L, De Wilde G, Van Damme P, Vanden Berghe W, Haegeman G: Transcriptional activation of the NF-βB p65 subunit by mitogen- and stress-activated protein kinase-1 (MSK1). EMBO J 2003, 22:1313-1324.
42. Soloaga A, Thomson S, Wiggin GR, Rampersaud N, Dyson MH, Hazzalin CA, Mahadevan LC, Arthur JS: MSK2 and MSK1 mediate the mitogen- and stress-induced phosphorylation of histone H3 and HMG-14. EMBO J 2003, 22:2788-2797.
43. Saklatvala J: The p38 MAP kinase pathway as a therapeutic target in inflammatory disease. Curr Opin Pharm 2004, 4:372-377.
44. Zhang J, Salojin KV, Gao JX, Cameron MJ, Bergerot I, Delovitch TL: p38 mitogen-activated protein kinase mediates signal integration of TCR/CD28 costimulation in primary murine T cells. J Immunol 1999, 162:3819-3829.
45. Cannons JL, Choi Y, Watts TH: Role of TNF receptor-associated factor 2 and p38 mitogen-activated protein kinase activation during 4-1BB-dependent immune response. J Immunol 2000, 165:6193-6204.
46. Harlin H, Podack E, Boothby M, Alegre M-L: TCR-independent CD30 signaling selectively induces IL-13 production via a TNF receptor-associated factor/p38 mitogen-activated protein kinase-dependent mechanism. J Immunol 2002, 169:2451-2459.
47. Labuda T, Sundstedt A, Dohlsten M: Selective induction of p38 mitogen-activated protein kinase activity following A6H costimulation in primary human CD4+ T cells. Int Immunol 2000, 12:253-261.
48. Yamochi T, Yamochi T, Aytac U, Sato T, Sato K, Ohnuma K, McKee KS, Morimoto C, Dang NH: Regulation of p38 phosphorylation and topoisomerase II alpha expression in the B-cell lymphoma line jiyoye by CD26/ dipeptidyl peptidase IV is associated with enhanced in vitro and in vivo sensitivity to doxorubicin. Cancer Res 2005, 65:1973-1983.
49. Luo H, Yu G, Wu Y, Wu J: EphB6 crosslinking results in costimulation of T cells. J. Clin Invest 2002, 110:1141-1150.
50. Okamoto N, Tezuka K, Kato M, Abe R, Tsuji T: P13-kinase and MAP-kinase signaling cascades in AILIM/ICOS- and CD28-costimulated T-cells have distinct functions between cell proliferation and IL-10 production. Biochem Biophys Res Commun 2003, 310:691-702.
51. Skapenko A, Lipsky PE, Kraetsch HG, Kalden JR, Schulze-Koops H: Antigen-independent Th2 cell differentiation by stimulation of CD28: regulation via IL-4 gene expression and mitogen-activated protein kinase activation. J Immunol 2001, 166:4283-4292.
52. Zhang S, Kaplan MH: The p38 mitogen-activated protein kinase is required for IL-12-induced IFN-γ expression. J Immunol 2000, 165:1374-1380.
53. Hunt AE, Williams LM, Lali FV, Foxwell BM: IL-4 Regulation of p38 MAPK signalling is dependent on cell type. Cytokine 2002, 18:295-303.
54. Crawley JB, Rawlinson L, Lali FV, Page TH, Saklatvala J, Foxwell BM: T cell proliferation in response to interleukins 2 and 7 requires p38 MAP kinase activation. J Biol Chem 1997, 272: 15023-15027.
55. Hirst SJ, Hallsworth MP, Peng Q, Lee TH: Selective induction of eotaxin release by interleukin-13 or interleukin-4 in human airway smooth muscle cells is synergistic with interleukin-1 β and is mediated by the interleukin-4 receptor α-chain. Am J Respir Crit Care Med 2002, 165:1161-1171.
56. Canfield S, Lee Y, Schroder A, Rothman P: Cutting edge: IL-4 induces suppressor of cytokine signaling-3 expression in B cells by a mechanism dependent on activation of p38 MAPK. J Immunol 2005, 174:2494-2498.
57. Yang J, Zhu H, Murphy TL, Ouyang W, Murphy KM: IL-18-stimulated GADD45 β required in cytokine-induced, but not TCR-induced, IFN-γ production. Nat Immunol 2001, 2:157-164.
58. Yu JJ, Tripp CS, Russell JH: Regulation and phenotype of an innate Th1 cell: role of cytokines and the p38 kinase pathway J Immunol 2003, 171:6112-6118.
59. Rincon M, Enslen H, Raingeaud J, Recht M, Zapton T, Su MS, Penix LA, Davis RJ, Flavell RA: Interferon-gamma expression by Th1 effector T cells mediated by the p38 MAP kinase signaling pathway. EMBO J 1998, 17:2817-2829.
60. Dodeller F, Skapenko A, Kalden JR, Lipsky PE, Schulze-Koops H: The p38 mitogen activated protein kinase regulates effector functions of primary human CD4 T cells. Eur J Immunol 2005, 35:3631-3642.
61. Schafer PH, Wadsworth SA, Wang L, Siekierka JJ: p38 alpha mitogen-activated protein kinase is activated by CD28- mediated signaling and is required for IL-4 production by human CD4+CD45RO+ T cells and Th2 effector cells. J Immunol 1999, 162:7110-7119.
62. Smith JL, Collins I, Chandramouli GV, Butscher WG, Zaitseva E, Freebern WJ, Haggerty CM, Doseeva V, Gardner K: Targeting combinatorial transcriptional complex assembly at specific modules within the interleukin-2 promoter by the immuno-suppressant. J Biol Chem 2003, 278:41034-41046.
63. Ohkusu-Tsukada K, Tominaga N, Udono H, Yui K: Regulation of the maintenance of peripheral T-cell anergy by TAB1-mediated p38α activation. Mol Cell Biol 2004, 24:6957-6966.
64. Veiopoulou C, Kogopoulou O, Tzakos E, Mavrothalassitis G, Mitsias D, Karafoulidou A, Paliogianni F, Moutsopoulos HM, Thyphronitis G: IL-2 and IL-10 production by human CD4+ T cells is differentially regulated by p38: mode of stimulation-dependent regulation of IL-2. Neuroimmunomodulation 2004, 11:199-208.
65. Schafer PH, Wang L, Wadsworth SA, Davis JE, Siekierka JJ: T cell activation signals up-regulate p38 mitogen-activated protein kinase activity and induce TNF-alpha production in a manner distinct from LPS activation of monocytes. J Immunol 1999, 162:659-668.
66. Chen C-H, Zhang D-H, LaPorte JM, Ray A: Cyclic AMP activates p38 mitogen-activated protein kinase in Th2 cells: phosphorylation of GATA-3 and stimulation of Th2 cytokine gene expression. J Immunol 2000, 165:5597-5605.
67. Song GY, Chung C-S, Chaudry IH, Ayala A: MAPK p38 antagonism as a novel method of inhibiting lymphoid immune suppression in polymicrobial sepsis. Am J Physiol Cell Physiol 2001, 281:C662-C669.
68. Mori A, Kaminuma O, Miyazawa K, Ogawa K, Okudaira H, Akiyama K: p38 mitogen-activated protein kinase regulates human T cell IL-5 synthesis. J Immunol 1999, 163:4763-4771.
69. Foey AD, Parry SL, Williams LM, Feldmann M, Foxwell BMJ, Brennan FM: Regulation of monocyte IL-10 synthesis by endogenous IL-1 and TNF-α: role of the p38 and p42/44 mitogen-activated protein kinases. J Immunol 1998, 160:920-928.
70. Rao A, Luo C, Hogan PG: Transcription factors of the NFAT family: regulation and function. Annu Rev Immunol 1997, 80: 29-36.
71. Kiani A, Garcia-Cozar FJ, Habermann I, Laforsch S, Aebischer T, Ehninger G, Rao A: Regulation of interferon-gamma gene expression by nuclear factor of activated T cells. Blood 2001, 98:1480-1488.
72. Brogdon JL, Leitenberg D, Bottomly K: The potency of TCR signaling differentially regulates NFATc/p activity and early IL-4 transcription in naive CD4+ T cells. J Immunol 2002, 168:3825-3832.
73. Wu, SC Hsu CC, Shih HM, Lai MZ: Nuclear factor of activated T cells c is a target of p38 mitogen-activated protein kinase in T cells. Mol Cell Biol 2003, 23:6442-6454.
74. Gomez del Arco P, Martinez-Martinez S, Maldonado JL, Ortega-Perez I, Redondo JM: A role for the p38 MAP kinase pathway in the nuclear shuttling of NFATp. J Biol Chem 2000, 275:13872-13878.
75. Berberich-Siebelt F, Klein-Hessling S, Hepping N, Santner-Nanan B, Lindemann D, Schimpl A, Berberich I, Serfling E: C/EBPbeta enhances IL-4 but impairs IL-2 and IFN-gamma induction in T cells. Eur J Immunol 2000, 30:2576-2585.
76. Shuai K, Liu B: Regulation of JAK-STAT signalling in the immune system. Nat Rev Immunol 2003, 3:900-911.
77. Decker T, Kovarik P: Serine phosphorylation of STATs. Onco-gene 2000, 19:2628-2637.
78. Morinobu A, Gadina M, Strober W, Visconti R, Fornace A, Montagna C, Feldman GM, Nishikomori R, O'Shea JJ: STAT4 serine phosphorylation is critical for IL-12-induced IFN-γ production but not for cell proliferation. Proc Natl Acad Sci 2002, 99: 12281-12286.
79. Visconti R, Gadina M, Chiariello M, Chen EH, Stancato LF, Gutkind JS, O'Shea JJ: Importance of the MKK6/p38 pathway for interleukin-12-induced STAT4 serine phosphorylation and transcriptional activity. Blood 2000, 96:1844-1852.
80. Chi H, Lu B, Takekawa M, Davis RJ, Flavell RA: GADD45beta/GADD45gamma and MEKK4 comprise a genetic pathway mediating STAT4-independent IFNgamma production in T cells. EMBO J 2004, 23:1576-1586.
81. Ma W, Lim W, Gee K, Aucoin S, Nandan D, Kozlowski M, Diaz-Mitoma F, Kumar A: The p38 mitogen-activated kinase pathway regulates the human interleukin-10 promoter via the activation of Sp1 transcription factor in lipopolysaccharide-stimulated human macrophages. J Biol Chem 2001, 276: 13664-13674.
82. Mayr B, Montminy M: Transcriptional regulation by the phosphorylation-dependent factor CREB. Nat Rev Mol Cell Biol 2001, 2:599-609.
83. Tan Y, Rouse J, Zhang A, Cariati S, Cohen P, Comb MJ: FGF and stress regulate CREB and ATF-1 via a pathway involving p38 MAP kinase and MAPKAP kinase-2. EMBO J. 1996, 15:4629-4642.
84. Samten B, Howard ST, Weis SE, Wu S, Shams H, Townsend JC, Safi H, Barnes PF: Cyclic AMP response element-binding protein positively regulates production of IFN-γ by T cells in response to a microbial pathogen J Immunol 2005, 174:6357-6363.
85. Zhang F, Rincon M, Flavell RA, Aune TM: Defective Th function induced by a dominant-negative cAMP response element binding protein mutation is reversed by Bcl-2. J Immunol 2000, 165:1762-1770.
86. 2+/calmodulin-dependent protein kinase IV. Mol Cell Biol 2002, 22:23-29.
87. Zhang F, Wang DZ, Boothby M, Penix L, Flavell RA, Aune TM: Regulation of the activity of IFN-γ promoter elements during Th cell differentiation. J Immunol 1998, 161:6105-6112.
88. Thomson S, Clayton AL, Hazzalin CA, Rose S, Barratt MJ, Mahadevan LC: The nucleosomal response associated with immediate-early gene induction is mediated via alternative MAP kinase cascades: MSK1 as a potential histone H3/HMG-14 kinase. EMBO J 1999, 18:4779-4793.
89. Saccani S, Pantano S, Natoli G: p38-Dependent marking of inflammatory genes for increased NF-κB recruitment. Nat Immunol 2002, 3:69-75.
90. Winzen R, Kracht M, Ritter B, Wilhelm A, Chen CY, Shyu AB, Muller M, Gaestel M, Resch K, Holtmann H: The p38 MAP kinase pathway signals for cytokine-induced mRNA stabilization via MAP kinase-activated protein kinase 2 and an AU-rich region-targeted mechanism. EMBO J 1999, 18:4969-4980.
91. Rousseau S, Morrice N, Peggie M, Campbell DG, Gaestel M, Cohen P: Inhibition of SAPK2a/p38 prevents hnRNP A0 phosphorylation by MAPKAP-K2 and its interaction with cytokine mRNAs. EMBO J 2002, 21:6505-6514.
92. Stoecklin G, Stoeckle P, Lu M, Muehlemann O, Moroni C: Cellular mutants define a common mRNA degradation pathway targeting cytokine AU-rich elements. RNA 2001, 7:1578-1588.
93. Ridley SH, Dean JLE, Sarsfield SJ, Brook M, Clark AR, Saklatvala J: A p38 MAP kinase inhibitor regulates stability of interleukin-1-induced cyclooxygenase-2 mRNA. FEBS Letters 1998, 439: 75-80.
94. Pages G, Berra E, Milanini J, Levy AP, Pouysségur J: Stress-activated protein kinases (JNK and p38/HOG) are essential for vascular endothelial growth factor mRNA stability. J Biol Chem 2000, 275:26484-26491.
95. Montero L, Nagamine Y: Regulation by p38 mitogen-activated protein kinase of adenylate- and uridylate-rich element-mediated urokinase-type plasminogen activator (uPA) messenger RNA stability and uPA-dependent in vitro cell invasion. Cancer Res 1999, 59:5286-5293.
96. Ambrosino C, Mace G, Galban S, Fritsch C, Vintersten K, Black E, Gorospe M, Nebreda AR: Negative feedback regulation of MKK6 mRNA stability by p38α mitogen-activated protein kinase. Mol Cell Biol 2003, 23:370-381.
97. Chrestensen CA, Schroeder MJ, Shabanowitz J, Hunt DF, Pelo JW, Worthington MT, Sturgill TW: MAPKAP kinase 2 phosphorylates tristetraprolin on in vivo sites including Ser178, a site required for 14-3-3 binding. J Biol Chem 2004, 279:10176-10184.
98. Stoecklin G, Stubbs T, Kedersha N, Wax S, Rigby WF, Blackwell TK, Anderson P: MK2-induced tristetraprolin:14-3-3 complexes prevent stress granule association and ARE-mRNA decay. EMBO J 2004, 23:1313-1324.
99. Rigby WFC, Roy K, Collins J, Rigby S, Connolly JE, Bloch DB, Brooks SA: Structure/function analysis of tristetraprolin (TTP): p38 stress-activated protein kinase and lipopolysaccharide stimulation do not alter TTP function. J Immunol 2005, 174: 7883-7893.
100. Lindsten T, June CH, Ledbetter JA, Stella G, Thompson CB: Regulation of lympholkine messenger RNA stability by a surface-mediated T cell activation pathway. Science 1989, 244: 339-343.
101. Butler NS, Monick MM, Yarovinsky TO, Powers LS, Hunninghake GW: Altered IL-4 mRNA stability correlates with Th1 and Th2 bias and susceptibility to hypersensitivity pneumonitis in two inbred strains of mice. J Immunol 2002, 169:3700-3709.
102. Foxwell B, Andreakos E, Brennan F, Feldmann M, Smith C, Conron M: Prospects for the development of small molecular weight compounds to replace anti-tumour necrosis factor biological agents. Ann Rheum Dis 2003, 62:90ii-93.
103. English JM, Cobb MH: Pharmacological inhibitors of MAPK pathways. Trends Pharm Sci 2002, 23:40-45.
104. Dumas J, Hatoum-Mokdad H, Sibley RN, Smith RA, Scott WJ, Khire U, Lee W, Wood J, Wolanin D, Cooley J: Synthesis and pharmacological characterization of a potent, orally active p38 kinase inhibitor. Bioorg Med Chem Lett 2002, 12:1559-1562.
105. Revesz L, Blum E, Di Padova FE, Buhl T, Feifel R, Gram H, Hiestand P, Manning U, Rucklin G: Novel p38 inhibitors with potent oral efficacy in several models of rheumatoid arthritis. Bioorg Med Chem Lett 2004, 14:3595-3599.
106. Barone FC, Irving EA, Ray AM, Lee JC, Kassis S, Kumar S, Badger AM, White RF, McVey MJ, Legos JJ, et al.: SB 239063, a second-generation p38 mitogen-activated protein kinase inhibitor, reduces brain injury and neurological deficits in cerebral focal ischemia. J Pharmacol Exp Ther 2001, 296:312-321.
107. Badger AM, Bradbeer JN, Votta B, Lee JC, Adams JL, Griswold DE: Pharmacological profile of SB 203580, a selective inhibitor of cytokine suppressive binding protein/p38 kinase, in animal models of arthritis, bone resorption, endotoxin shock and immune function. J Pharmacol Exp Ther 1996, 279: 1453-1461.
108. Badger AM, Griswold DE, Kapadia R, Blake S, Swift BA, Hoffman SJ, Stroup GB, Webb E, Rieman DJ, Gowen M, et al.: Disease-modifying activity of SB 242235, a selective inhibitor of p38 mitogen-activated protein kinase, in rat adjuvant-induced arthritis. Arthritis Rheum 2000, 43:175-183.
109. de Dios A, Shih C, Lopez de Uralde B, Sanchez C, del Prado M, Martin Cabrejas LM, Pleite S, Blanco-Urgoiti J, Lorite MJ, Nevill CRJ, et al.: Design of potent and selective 2-aminobenzimidazole-based p38alpha MAP kinase inhibitors with excellent in vivo efficacy. J Med Chem 2005, 48:2270-2273.
110. Wada Y, Nakajima-Yamada T, Yamada K, Tsuchida J, Yasumoto T, Shimozato T, Aoki K, Kimura T, Ushiyama S: R-130823, a novel inhibitor of p38 MAPK, ameliorates hyperalgesia and swelling in arthritis models. Eur J Pharmacol 2005, 506:285-295.
111. Fijen JW, Zijlstra JG, De Boer P, Spanjersberg R, Tervaert JW, Van Der Werf TS, Ligtenberg JJ, Tulleken JE: Suppression of the clinical and cytokine response to endotoxin by RWJ-67657, a p38 mitogen-activated protein-kinase inhibitor, in healthy human volunteers. Clin Exp Immunol 2001, 124:16-20.
112. Branger J, van den Blink B, Weijer S, Madwed J, Bos CL, Gupta A, Yong C-L, Polmar SH, Olszyna DP, Hack CE, et al.: Anti-inflammatory effects of a p38 mitogen-activated protein kinase inhibitor during human endotoxemia. J Immunol 2002, 168:4070-4077.
113. Vertex Pharmaceuticals: Preliminary phase IIa data for VX-702 demonstrate tolerability and reduction in C-reactive protein in cardiovascular patients. Vertex press release, 18 October 2004 [www.vpharm.com/Pressreleases2004/pr101804.html].
114. Trifilieff A, Keller TH, Press NJ, Howe T, Gedeck P, Beer D, Walker C: CGH2466, a combined adenosine receptor antagonist, p38 mitogen-activated protein kinase and phosphodiesterase type 4 inhibitor with potent in vitro and in vivo anti-inflammatory activities. Br J Pharmacol 2005, 144:1002-1010.
115. Underwood DC, Osborn RR, Kotzer CJ, Adams JL, Lee JC, Webb EF, Carpenter DC, Bochnowicz S, Thomas HC, Hay DWP, et al.: SB 239063, a potent p38 MAP kinase inhibitor, reduces inflammatory cytokine production, airways eosinophil infiltration, and persistence. J Pharmacol Exp Ther 2000, 293:281-288.
116. Duan W, Chan JHP, McKay K, Crosby JR, Choo HH, Leung BP, Karras JG, Wong WSF: Inhaled p38α mitogen-activated protein kinase antisense oligonucleotide attenuates asthma in mice. Am J Respir. Crit Care Med 2005, 171:571-578.
117. Tigani B, Di Padova F, Zurbrugg S, Schaeublin E, Revesz L, Fozard JR, Beckmann N: Effects of a mitogen-activated protein kinase inhibitor on allergic airways inflammation in the rat studied by magnetic resonance imaging. Eur J Pharmacol 2003, 482:319-324.
118. Kumar S, Boehm J, Lee JC: p38 MAP kinases: key signalling molecules as therapeutic targets for inflammatory diseases. Nat Rev Drug Discov 2003, 2:717-726.
119. Raingeaud J, Gupta S, Dickens M, Han J: Pro-inflammatory cytokines and environmental stress cause p38 mitogen-activated protein kinase activation by dual phosphorylation on tyrosine and threonine. J Biol Chem 1995, 270:7420-7426.
120. Janknecht R, Hunter T: Convergence of MAP kinase pathways on the ternary complex factor Sap-1a. EMBO J 1997, 16:1620-1627.
121. Wang X-Z, Ron D: Stress-induced phosphorylation and activation of the transcription factor CHOP (GADD153) by p38 MAP kinase. Science 1996, 272:1347-1349.
122. Huang C, Ma W-Y, Maxiner A, Sun Y, Dong Z: p38 kinase mediates UV-induced phosphorylation of p53 protein at serine 389. J. Biol. Chem. 1999, 274:12229-12235.
123. Zhao M, New L, Kravchenko VV, Kato Y, Gram H, di Padova F, Olson EN, Ulevitch RJ, Han J: Regulation of the MEF2 family of transcription factors by p38. Mol Cell Biol 1999, 19:21-30.
124. Han J, Jiang Y, Li Z, Kravchenko VV, Ulevitch RJ: Activation of the transcription factor MEF2C by the MAP kinase p38 in inflammation. Nature 1997, 386:296-299.
125. Engelman JA, Lisanti MP, Scherer PE: Specific inhibitors of p38 mitogen-activated protein kinase block 3T3-L1 adipogenesis. J Biol Chem 1998, 273:32111-32120.
126. Rouse J, Cohen P, Trigon S, Morange M, Alonso-Llamazares A, Zamanillo D, Hunt T, Nebreda AR: A novel kinase cascade triggered by stress and heat shock that stimulates MAPKAP kinase-2 and posphorylation of the small heat shock proteins. Cell 1994, 78:1027-1037.
127. McLaughlin MM, Kumar S, McDonnell PC, Van Horn S, Lee JC, Livi GP, Young PR: Identification of mitogen-activated protein (MAP) kinase-activated protein kinase-3, a novel substrate of CSBP p38 MAP kinase. J Biol Chem 1996, 271: 8488-8492.
128. Waskiewicz AJ, Flynn A, Proud CG, Cooper JA: Mitogen-activated protein kinases activate the serine/threonine kinases Mnk1 and Mnk2. EMBO J 1997, 16:1909-1920.
129. New L, Jiang Y, Zhao M, Liu K, Zhu W, Flood LJ, Kato Y, Parry GC, Han J: PRAK, a novel protein kinase regulated by the p38 MAP kinase. EMBO J 1998, 17:3372-3384.
130. Deak M, Clifton AD, Lucocq LM, Alessi DR: Mitogen- and stress-activated protein kinase-1 (MSK1) is directly activated by MAPK and APK2/p38, and may mediate activation of CREB. EMBO J 1998, 17:4426-4441.